Status of the Parkinson’s disease gene family expression in non-small-cell lung cancer

World Journal of Surgical Oncology

Ji Gang Dai¹  Dong Zhou¹  Xu Feng Deng¹  Hong Zheng²  Quan Xing Liu¹ 

[1]Department of Thoracic Surgery, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China

[2]Institute of Immunology of PLA, Third Military Medical University, Chongqing 400037, China

关键词: mRNA;    Gene;    Parkinson’s disease;    Non-small-cell lung cancer;    Carcinoma;   

Others  :  1223987
DOI  :  10.1186/s12957-015-0646-y

 received in 2015-05-17, accepted in 2015-07-14,  发布年份 2015

【 摘 要 】

Background

The purpose of this study is to detect the Parkinson’s disease gene family mRNA relative expression in the non-small-cell lung cancer (NSCLC) tumor tissue and analyze the association between tumor characteristics and the Parkinson’s disease gene family.

Methods

Tumor tissue and tumor-adjacent tissue of 114 NSCLC patients were collected and SYBR quantitative analysis was used to detect the relative expression level of nine Parkinson’s disease gene mRNAs. Then, paired sample test, two-sided Student’s t-test, or two-sided Wilcoxon rank sum test was performed to analyze the mRNA relative expression level of nine Parkinson’s disease gene mRNAs in different gender, tumor histology, and tumor stage.

Results

Overexpression in the tumors was detected in 46/114 (40.35 %) PARK1/4, 74/114 (64.91 %) PARK2, 104/114 (91.23 %) PARK5, 95/114 (83.33 %) PARK6, 80/114 (70.18 %) PARK7, 55/114 (48.25 %) PARK8, 100/114 (87.72 %) PARK9, 55/114 (48.25 %) PARK15, and 99/114 (86.84 %) glucocerebrosidase (GBA). Five genes PARK5 (91.23 %), PARK6 (83.33 %), PARK7 (70.18 %), PARK9 (87.72 %), and GBA (86.84 %) were supposed to be overexpressed in the lung tumor tissues compared with tumor-adjacent tissues. There was no significant difference in PARK1/4, PARK2, PARK5, PARK9, and GBA mRNA expression by different tumor stage, whereas, PARK6, PARK7, PARK8, and PARK15 mRNA expression were found to have significant difference in the comparison of different tumor stages. The expression of PARK6 (P = 0.01, P = 0.03) and PARK15 (P < 0.001, P < 0.001) were significantly higher in stages I and II when compared with stage III, respectively. NSCLC patients in stage I showed the higher expression PARK7 compared to the patients in stage II (P = 0.003).

Conclusions

The high expression of PARK6, PARK7, and PARK15 might lead to the occurrence of a primary NSCLC tumor, and the tumor with a decreasing expression of these three genes tends to be stages II and III. The results of our study indicate that the Parkinson’s disease gene family may be a potential marker for the prediction of NSCLC.

【 授权许可】

   
2015 Liu et al.

【 图 表 】

Fig. 1.

【 参考文献 】

• [1]Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008; 79:368-376.
• [2]Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276:2045–7.
• [3]Hardy J. Genetic analysis of pathways to Parkinson disease. Neuron. 2010; 68:201-206.
• [4]Sharma JC, Vassallo M. Prognostic significance of weight changes in Parkinson’s disease: the Park-weight phenotype. Neurodegener Dis Manag. 2014; 4:309-316.
• [5]Fiala O, Zahorakova D, Pospisilova L, Kucerova J, Matejckova M, Martasek P et al.. Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson’s disease. PLoS One. 2014; 9: Article ID e107585
• [6]Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. Occurrence of different cancers in patients with Parkinson’s disease. BMJ. 1995; 310:1500-1501.
• [7]Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S et al.. Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol. 2000; 247:429-434.
• [8]Olsen JH, Friis S, Frederiksen K, Mellemkjaer L, Møller H. Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer. 2005; 92:201-205.
• [9]Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK et al.. Risk of cancer after the diagnosis of Parkinson’s disease: a historical cohort study. Mov Disord. 2005; 20:719-725.
• [10]Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM et al.. Comorbid cancer in Parkinson’s disease. Mov Disord. 2010; 25:1809-1817.
• [11]O’Flanagan CH, Morais VA, Wurst W, De Strooper B, O'Neill C. The Parkinson’s gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes. Oncogene. 2015; 34:1363-1374.
• [12]Cao J, Lou S, Ying M, Yang B. DJ-1 as a human oncogene and potential therapeutic target. Biochem Pharmacol. 2015; 93:241-250.
• [13]Cordeiro Y, Foguel D, Silva JL. Pressure-temperature folding landscape in proteins involved in neurodegenerative diseases and cancer. Biophys Chem. 2013; 183:9-18.
• [14]Kawashima M, Suzuki SO, Doh-ura K, Iwaki T. Alpha-synuclein is expressed in a variety of brain tumors showing neuronal differentiation. Acta Neuropathol. 2000; 99:154-160.
• [15]Matsuo Y, Kamitani T. Parkinson’s disease-related protein, alpha-synuclein, in malignant melanoma. PLoS One. 2010; 5: Article ID e10481
• [16]Bruening W, Giasson BI, Klein-Szanto AJ, Lee VM, Trojanowski JQ, Godwin AK et al.. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer. 2000; 88:2154-2163.
• [17]Hod Y. Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J Cell Biochem. 2004; 92:1221-1233.
• [18]MacKeigan JP, Clements CM, Lich JD, Pope RM, Hod Y, Ting JP. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 2003; 63:6928-6934.
• [19]Devine MJ, Plun-Favreau H, Wood NW. Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer. 2011; 11:812-823.
• [20]Kennedy CH, Pass HI, Mitchell JB. Expression of human MutT homologue (hMTH1) protein in primary non-small-cell lung carcinomas and histologically normal surrounding tissue. Free Radic Biol Med. 2003; 34:1447-1457.
• [21]Laman H, Funes JM, Ye H, Galinanes-Garcia L, Hara E, Knowles P. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6. EMBO J. 2005;24:3104–16.
• [22]DOSHAY LJ. Problem situations in the treatment of paralysis agitans. J Am Med Assoc. 1954; 156:680-684.
• [23]WARBURG O. On the origin of cancer cells. Science. 1956; 123:309-314.
• [24]Iyer AM, van Scheppingen J, Milenkovic I, Anink JJ, Adle-Biassette H, Kovacs GG. mTOR hyperactivation in down syndrome hippocampus appears early during development. J Neuropathol Exp Neurol. 2014;73:671–83.
• [25]Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal. 2014; 26:2694-2701.
• [26]O’ Neill C. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer’s disease. Exp Gerontol. 2013; 48:647-653.
• [27]Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8:627-644.
• [28]Chia S, Gandhi S, Joy AA, Edwards S, Gorr M, Hopkins S. Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer. Curr Oncol. 2015;22:33–48.
• [29]Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y, Farajnia S. Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action. Pharmacol Res. 2015;93:1–10.
• [30]Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
• [31]Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010; 10:190-198.